The effects of HLA-DRB1*08:03 on laboratory test results in patients with iTTP in the acute phase
| . | HLA-DRB1*08:03 . | . | |
|---|---|---|---|
| . | Positive (n = 16) . | Negative (n = 36) . | P . |
| ADAMTS13 activity (%) | <0.5 (<0.5-<0.5) | <0.5 (<0.5-<0.5) | .766 |
| ADAMTS13 inhibitor (BU/mL) | 3.15 (1.78-4.65) | 2.0 (1.0-3.5) | .254 |
| Platelet count (109/L) | 15.5 (7.0-32.3) | 11.0 (9.0-14.0) | .211 |
| Hemoglobin (g/dL) | 7.95 (6.93-9.63) | 8.0 (7.2-9.3) | .873 |
| LDH (U/L) | 742 (509-965) | 1138 (725-1598) | .017 |
| Total bilirubin (mg/dL) | 2.25 (1.2-2.43) | 3.3 (2.2-4.9) | .015 |
| Serum creatine (mg/dL) | 0.8 (0.68-0.9) | 1.0 (0.7-1.1) | .103 |
| . | HLA-DRB1*08:03 . | . | |
|---|---|---|---|
| . | Positive (n = 16) . | Negative (n = 36) . | P . |
| ADAMTS13 activity (%) | <0.5 (<0.5-<0.5) | <0.5 (<0.5-<0.5) | .766 |
| ADAMTS13 inhibitor (BU/mL) | 3.15 (1.78-4.65) | 2.0 (1.0-3.5) | .254 |
| Platelet count (109/L) | 15.5 (7.0-32.3) | 11.0 (9.0-14.0) | .211 |
| Hemoglobin (g/dL) | 7.95 (6.93-9.63) | 8.0 (7.2-9.3) | .873 |
| LDH (U/L) | 742 (509-965) | 1138 (725-1598) | .017 |
| Total bilirubin (mg/dL) | 2.25 (1.2-2.43) | 3.3 (2.2-4.9) | .015 |
| Serum creatine (mg/dL) | 0.8 (0.68-0.9) | 1.0 (0.7-1.1) | .103 |
Median (25%-75%).